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Abstract: The term necrosis is commonly applied to cells that have died via a non-specific pathway
or mechanism but strictly is the description of the degradation processes involved once the plasma
membrane of the cell has lost integrity. The signalling pathways potentially involved in accidental
cell death (ACD) or oncosis are under-studied. In this study, the flow cytometric analysis of the
intracellular antigens involved in regulated cell death (RCD) revealed the phenotypic nature of cells
undergoing oncosis or necrosis. Sodium azide induced oncosis but also classic apoptosis, which
was blocked by zVAD (z-Vla-Ala-Asp(OMe)-fluoromethylketone). Oncotic cells were found to be
viability+ve/caspase-3–ve/RIP3+ve/–ve (Receptor-interacting serine/threonine protein kinase 3). These
two cell populations also displayed a DNA damage response (DDR) phenotype pH2AX+ve/PARP–ve,
cleaved PARP induced caspase independent apoptosis H2AX–ve/PARP+ve and hyper-activation or
parthanatos H2AX+ve/PARP+ve. Oncotic cells with phenotype cell viability+ve/RIP3–ve/caspase-3–ve
showed increased DDR and parthanatos. Necrostatin-1 down-regulated DDR in oncotic cells and
increased sodium azide induced apoptosis. This flow cytometric approach to cell death research
highlights the link between ACD and the RCD processes of programmed apoptosis and necrosis.
Keywords: accidental cell death; oncosis; DDR; parthanatos; flow cytometry
1. Introduction
The recent re-definition of cell death from Type I (programmed cell death by apoptosis),
Type II (autophagic cell death), and Type III (programmed necrosis) to programmed cell death
(PCD, homeostatic and embryonic), accidental cell death (ACD, oncosis), and regulated cell death
(RCD), which includes apoptosis, necroptosis, autophagy, parthanatos or hyper-activation of Poly
(ADP-ribose) polymerase (PARP) caused by an excessive DNA damage response (DDR, e.g., by pH2AX
phospho H2AX histone) has been advantageous in understanding the complexity of cell death. RIP1-
(Receptor-interacting serine/threonine protein kinase 1) dependent apoptosis or RIP1/RIP3/caspase-3
cells not being included highlights that the cell death nomenclature should be reviewed on a regular
basis [1–5]. Programmed or regulated necrosis now includes necroptosis and parthanatos, amongst
other forms of reported programmed cell death. However, necrosis is also the term commonly used to
indicate the presence of dead cells that have lost plasma membrane integrity by any cell death pathway,
but is strictly a reference to the degradation of the cell contents and plasma membrane after death [6–10].
The term oncosis or ACD is a better description of cell death induced by mechanical, chemical, and
environmental factors that cause a rapid decrease in intracellular ATP leading to the deactivation
of Na+ and K+-ATPase, resulting in an influx of Na+, Cl–, and Ca2+ ions. The cell then undergoes
osmosis and swelling with a bursting of cell organelles and the plasma membrane [11]. Uncoupling
protein 2 (UCP-2), located in the inner mitochondrial membrane where protons are pumped by UCP-2
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into the mitochondrial matrix or the intermembrane space, which then regulates ATP and superoxide
production is modestly up-regulated by oncosis, resulting in a rapid depolarization of the mitochondrial
membrane, which has been measured by flow cytometry [12,13]. The signal pathways involved in
oncosis are under studied, so little information is known about these mechanisms compared to the
knowledge of pathways in RCD [1,2,6].
In contrast to oncosis, classic apoptosis is caspase-3 dependent and these cells form blebs on the
surface of the plasma membrane with a gradual loss in mitochondrial membrane potential and hence a
gradual lowering of intracellular ATP. The generation of reactive oxygen species (ROS) and loss of
cytochrome c from the mitochondria to the cytoplasm results in activation of caspases and generation
of apoptosomes and DNA fragmentation, accompanied with cell shrinkage and the formation of
apoptotic bodies [1,2,8,14].
Until recently, necrotic or oncotic cells were measured via flow cytometry using the Annexin V
assay in which such cells are gated as cell viability+ve/AnnexinV–ve and numerous researchers have
attempted to understand this dead cell population with varying success [13,15,16]. In our laboratory,
mitochondrial and plasma membrane dysfunction were detected by the multiplexing of mitochondrial
and plasma membrane probes into the Annexin V assay, leading to a better understanding of the
biological processes occurring in this oncotic population [13,15,16]. The recent development of a
polychromatic flow cytometric assay in this laboratory, which identifies most RCDs simultaneously
and demonstrates pathways affected by use of pan-caspase and RIP1 protein blockers zVAD and
necrostatin-1 (Nec-1), led us to re-investigate oncotic cell death for potential pathways by comparison
with apoptosis. The markers measured by flow cytometry included a fixable cell viability marker,
activated caspase-3 (apoptosis), up-regulated RIP3 (necroptosis, or resting when not), pH2AX (DDR),
cleaved PARP (apoptosis), parthanatos, or hyper-activation of cleaved PARP (pH2AX/cleaved PARP;
Table 1, Figure S1). Potential modulation of the oncotic response to sodium azide was further
investigated by the use of zVAD and necrostatin-1 to evaluate if the oncotic signalling pathways can be
modified by these inhibitors before the cell loses plasma membrane permeability and the cell undergoes
oncosis [3,4,13,17–19]. This approach may indicate the nature of the oncotic cell phenotype and
highlight potential mechanisms that can modify the oncotic cellular response and the ACD connection
to RCD processes. This may increase the potential for the use of therapeutic drugs to target the ACD
process in the treatment of cancer.
Table 1. Cell description and phenotypes; Figure S1 provides a diagrammatical representation.
Cell Population Phenotypic Markers
Live resting (or necroptotic) Caspase-3–ve/Zombie NIR–ve/RIP3+ve
Live double negative (DN) Caspase-3–ve/Zombie NIR–ve/RIP3–ve
Early apoptosis (EAPO) Caspase-3+ve/Zombie NIR–ve/RIP3–ve
Live RIP1-dependent apoptosis (RIP1-APO) Caspase-3+ve/Zombie NIR–ve/RIP3+ve
Late apoptosis (LAPO) Caspase-3+ve/Zombie NIR+ve/RIP3–ve
Dead/necrotic/oncotic Caspase-3–ve/Zombie NIR+ve
Dead resting (or necroptotic) Caspase-3–ve/Zombie NIR+ve/RIP3+ve
Dead double negative (DN) Caspase-3–ve/Zombie NIR+ve/RIP3–ve
Dead RIP1-dependent apoptosis (RIP1-APO) Caspase-3+ve/Zombie NIR+ve/RIP3+ve
DNA damage response (DDR) pH2AX+ve/Cleaved PARP–ve
Hyper-activation of cleaved PARP/parthanatos pH2AX+ve/Cleaved PARP+ve
Cleaved PARP pH2AX–ve/Cleaved PARP+ve
2. Results
2.1. Induction of Oncosis
NaN3 induced early apoptosis (28%, Figure 1B, lower right quadrant) and lower levels of late
apoptotic (13%, Figure 1B, upper right quadrant) and oncotic cells (17%, Figure 1B, upper left quadrant)
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compared with untreated cells after 24 h (Figure 1A,B, see Materials and Methods section for details
of cell phenotype and gating strategy, Table 1, Figure S1). A lower incidence of live resting cells was
observed (RIP3+ve/caspase-3–ve, 44%, Figure 2C, upper left quadrant) but with more early apoptosis
after treatment (RIP3–ve/caspase-3+ve, 25%, Figure 2A,C, lower right quadrant). Dead cells arising from
NaN3 treatment showed less late apoptosis (25%, Figure 2D, lower right quadrant) than untreated cells
(Figure 2B).
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Figure 1. Cell death and caspase-3 activation assay. Cells were (A) untreated; (B) treated with 0.25% 
sodium azide (NaN3) for 24 h; (C) pre-treated with 20 µM zVAD for 2 h, then with 0.25% NaN3; (D) 
pre-treated with 60 μM necrostatin-1 (Nec-1) for 2 h, then with 0.25% NaN3; (E) pre-treated with 20 
μM zVAD and 60 μM Nec-1 for 2 h, then with 0.25% NaN3; (F) treated with 1 μM Etoposide (Etop) for 
24 h; (G) pre-treated with 20 μM zVAD for 2 h, then with 1 μM Etop; (H) pre-treated with 60 μM Nec-
1 for 2 h, then with 1 μM Etop; and (I) pre-treated with 20 μM zVAD and 60 μM Nec-1 for 2 h, then 
with 1 μM Etop. n = 3, % Mean ± % SEM; Student’s t-test: NS (not significant), * p < 0.05, ** p < 0.01**, 
*** p < 0.001; arrows indicate change compared with untreated cells. 
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Figure 2. RIP3 and caspase-3 activation analysis of oncosis. After gating on live and dead cells from a 
Zombie NIR vs. caspase3-BV650 dot-plot (A) untreated live and (B) dead Jurkat cells were analysed 
on a RIP3-PE vs. caspase-3-BV650 dot-plot with resting phenotype indicated by RIP3+ve/caspase-3–ve, 
apoptosis by RIP3–ve/caspase-3+ve, RIP1-dependent apoptosis RIP3+ve/caspase-3+ve, and double 
negative RIP3–ve/caspase-3–ve. Live and dead cells treated with (C,D) 0.25% NaN3 for 24 h; (E,F) pre-
treated with 20 μM zVAD for 2 h, then treated with 0.25% NaN3; (G,H)pre-treated with 60 μM Nec-1 
for 2 h, then treated with 0.25% NaN3; and (I,J) pre-treated with 20 μM zVAD and 60 μM Nec-1 for 2 
h, then treated with 0.25% NaN3, respectively. n = 3, % Mean ± % SEM, Student’s t–test: NS (not 
significant), * p < 0.05, ** p < 0.01**, *** p < 0.001; arrows indicate change compared with untreated cells. 
The oncotic cells resulting from NaN3 treatment were mainly double negative (55%) for RIP3 
and caspase-3 expression (dead resting oncotic cells, <10% caspase-3–ve/RIP3+ve, Figure 2D). 
After NaN3 treatment, the two live and dead apoptotic populations showed increased levels of 
pH2AX hyper-activation of cleaved PARP and a lower degree of apoptosis via cleaved PARP and 
DDR than untreated cells (Figures 3A–C, S1A,B,E,F,I,J,M,N). Whereas late apoptotic cells showed 
increased DDR (Figures 3C, S2B,E,M,J). The dead resting oncotic cells (Zombie+ve/caspase-3–ve/RIP3+ve) 
were, 31% negative for both H2AX and PARP, whereas the dead oncotic DN (Zombie+ve/caspase-3–
ve/RIP3–ve) cells were 57% negative for both markers (Figures 3A–C, S2O,P). The live and dead DN 
populations showed increased levels of parthanatos and DDR (Figures 3A–C, S2D,H,L,P). 
Figure 2. RIP3 and caspase-3 activation analysis of oncosis. After gating on live and dead cells from a
Zombie NIR vs. caspase3-BV650 dot-plot (A) untreated live and (B) dead Jurkat cells were analysed
on a RIP3-PE vs. caspase-3-BV650 dot-plot with resting phenotype indicated by RIP3+ve/caspase-3–ve,
apoptosis by RIP3–ve/caspase-3+ve, RIP1-dependent apoptosis RIP3+ve/caspase-3+ve, and double
negative RIP3–ve/caspase-3–ve. Live and dead cells treated with (C,D) 0.25% NaN for 24 h; (E,F)
pre-treated with 20 µM zVAD for 2 h, then treated with 0.25% NaN3; (G,H)pre-treated with 60 µM
Nec-1 for 2 h, then treated with 0.25% NaN3; and (I,J) pre-treated with 20 µM zVAD and 60 µM Nec-1
for 2 h, then treated with 0.25% NaN3, respectively. n = 3, % Mean ± % SEM, Student’s t–test: NS (not
significant), * p < 0.05, ** p < 0.01**, *** p < 0.001; arrows indicate change compared with untreated cells.
The oncotic cells resulting from NaN3 treatment were mainly double negative (55%) for RIP3 and
caspase-3 expression (dead resting oncotic cells, <10% caspase-3–ve/RIP3+ve, Figure 2D).
After NaN3 treatment, the two live and dead apoptotic populations showed increased
levels of pH2AX hyper-activation of cleaved PARP and a lower degree of apoptosis via cleaved
PARP and DDR than untreated cells (Figure 3A–C, Figure S1A,B,E,F,I,J,M,N). Whereas late
apoptotic cells showed increased DDR (Figure 3C, Figure S2B,E,M,J). The dead resting oncotic
cells (Zombie+ve/caspase-3–ve/RIP3+ve) were, 31% negative for both H2AX and PARP, whereas the dead
oncotic DN (Zombie+ve/caspase-3–ve/RIP3–ve) cells were 57% negative for both markers (Figure 3A–C,
Figure S2O,P). The live and dead DN populations showed increased levels of parthanatos and DDR
(Figure 3A–C, Figure S2D,H,L,P).
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Figure 3. Parthanatos/hyper-activation of cleaved PARP, apoptosis via cleaved PARP, and DDR 
analysis of oncosis. Untreated Jurkat cells, treated with 0.25% NaN3 for 24 h, or pre-treated with zVAD 
(20 μM) and/or Nec-1 (60 μM) for 2 h, then incubated with 0.25% NaN3. Gating live and dead cells 
from a Zombie NIR vs. caspase-3-BV650 plot then both were analysed on a RIP3-PE vs. caspase-3-
BV650 plot. Next, early and late apoptotic, necroptotic/resting, RIP1-dependent apoptotic, and double 
negative (DN) populations were analysed for pH2AX and cleaved PARP (Figures S2, S3). The 
incidence of (A) parthanatos/hyper-activation of cleaved PARP, (B) apoptosis via cleaved PARP, and 
(C) DDR were determined for all populations listed above. n = 3, % Mean, error bars % SEM, Student’s 
t-test; NS (not significant), * p < 0.05, ** p < 0.01**, *** p < 0.001 compared with untreated cells. 
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Figure 3. Parthanatos/hyper-activation of cleaved PARP, apoptosis via cleaved PARP, and DDR analysis
of oncosis. Untreated Jurkat cells, treated with 0.25% NaN3 for 24 h, or pre-treated with zVAD (20 µM)
and/or Nec-1 (60 µM) for 2 h, then incubated with 0.25% NaN3. Gating live and dead cells from a
Zombie NIR vs. caspase-3-BV650 plot then both were analysed on a RIP3-PE vs. caspase-3-BV650 plot.
Next, early and late apoptotic, necroptotic/resting, RIP1-dependent apoptotic, and double negative
(DN) populations were analysed for pH2AX and cleaved PARP (Figures S2, S3). The incidence of (A)
parthanatos/hyper-activation of cleaved PARP, (B) apoptosis via cleaved PARP, and (C) DDR were
determined for all populations listed above. n = 3, % Mean, error bars % SEM, Student’s t-test; NS (not
significant), * p < 0.05, ** p < 0.01**, *** p < 0.001 compared with untreated cells.
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2.2. Induction of Apoptosis
Induction of apoptosis with Etop showed an increase in early and late apoptosis as well as
oncotic cells compared with untreated cells (Figure 1A,F). Live and early apoptotic cells showed
increased levels of both types of apoptosis and the DN cells, whereas dead cells showed no such change
(Figure 2A,B and Figure 4A,B).
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Early and late apoptotic cells after Etop treatment showed increased pH2AX hyper-activation of 
cleaved PARP with a decrease in apoptosis via cleaved PARP compared with untreated cells (Figures 
5A,B, S2Q,U). Live RIP1-dependent cells, however, showed increased pH2AX hyper-activation of 
cleaved PARP and caspase-3-dependent apoptosis via cleaved PARP with decreased DDR (Figures 
5A–C, S2R). However, live and dead oncotic resting and DN phenotypes also showed increased 
parthanatos and caspase-3-independent apoptosis via cleaved PARP with no increase in DDR, except 
for an increase observed in the live resting population (Figures 5A–C, S2S,T,V,W,X). 
Figure 4. RIP3 an cas ase-3 acti ati a al sis of apoptosis. Gating on live an dead cells from
a Zombie NIR vs. caspase-3-BV650 plot followed by analysis on a RIP3-PE vs. caspase-3-BV650
plot with resting phenotype indicated by RIP3+ve/caspase-3–ve, apoptosis by RIP3–ve/caspase-3+ve,
RIP1-dependent apoptosis by RIP3+ve/caspase-3+ve and double negative by IP3 e/caspase-3–ve. (A,B)
Treated with 1 µM Etop for 24 h; (C,D), pre-treated ith 20 µ z for 2 h, then treated ith 1 µ
Etop; (E,F) pre-treated with 60 µ ec-1 for 2 h, then treated ith 1 µ Etop; and ( , ) pre-treated
with 20 µM zVAD and 60 µM Nec-1 for 2 h, then treated with 1 µ Etop. = 3, ean ± % SEM,
Student’s t–test: NS (not significant), * p < 0.05, ** p < 0.01**, *** p < 0.001; arro s indicate change
compared with untreated cells.
Early and late apoptotic cel s after t y er-activation of
cleaved PARP with a decrease in apo tosis via cleaved PARP compared with untreat d cells (Figure 5A,B
and Figure S2Q,U). Live RIP1-dependent cells, how ver, showed increased pH2AX hyper-activation of
cleaved PARP and caspase-3-dependent apo tosis via cleaved PARP with decreased DDR (Figure 5A–C
and Figure S2R). However, live an dead oncotic resting and DN phenotypes also showed increased
parthanatos and caspase-3-independent apoptosis via cleaved P P ith no increase in , except
for an increase observed in the live resting population (Figure 5A–C and Figure S2S,T,V,W,X).
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(60 μM) for 2 h, then incubated with 1 μM Etop for 24 h. Gating on live and dead cells from a Zombie 
NIR vs. caspase-3-BV650 plot then both were analysed on a RIP3-PE vs. caspase-3-BV650 plot. Early and 
late apoptotic, necroptotic/resting, RIP1-dependent apoptotic, and double negative (DN) populations 
were analysed for pH2AX and cleaved PARP (Figures S2,S4 for detailed information). The incidence of 
(A) parthanatos/hyper-activation of cleaved PARP, (B) apoptosis via cleaved PARP, and (C) DDR were 
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Figure 5. Parthanatos/hyper-activation of cleaved PARP, apoptosis via cleaved PARP, and DDR analysis
of apoptosis. Untreated Jurkat, treated with 1 µM Etop or pre-treated with zVAD (20 µM) and/or
Nec-1 (60 µM) for 2 h, then incubated with 1 µM Etop for 24 h. Gating on live and dead cells from a
Zombie NIR vs. caspase-3-BV650 plot then both were analysed on a RIP3-PE vs. caspase-3-BV650 plot.
Early and late apoptotic, necroptotic/resting, RIP1-dependent apoptotic, and double negative (DN)
populations were analysed for pH2AX and cleaved PARP (Figures S2,S4 for detailed information). The
incidence of (A) parthanatos/hyper-activation of cleaved PARP, (B) apoptosis via cleaved PARP, and (C)
DDR were determined for all populations listed above. Mean, error bars % SEM, Student’s t-test: NS
(not significant), * p < 0.05, ** p < 0.01**, *** p < 0.001 compared with untreated cells.
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2.3. Blockade of Caspases
Pre-treatment with zVAD to block the activation of caspases by NaN3 and Etop resulted in lower
levels of early apoptosis (<20%) and late apoptosis (<10%) with no change in the incidence of oncotic
cells (Figure 1C,G, Figure 2E,F and Figure 4C,D). The proportion of live DN (RIP3–ve/caspase-3–ve) and
dead oncotic cells (RIP3–ve/caspase-3–ve) increased after zVAD blockade of both drugs (Figure 2E,F
and Figure 4C,D).
After zVAD caspase blockade of NaN3 and Etop treatments, all live populations showed increased
H2AX hyper-activation of cleaved PARP or parthanatos compared with untreated cells but decreased
compared to drugs alone (Figure 3A, Figure 5A and Figure S3A–D, S4A–D). The live RIP1-dependent
apoptotic, resting, and DN cells from both treatments also showed increased levels of apoptosis via
cleaved PARP compared with untreated cells (early apoptosis showed a decrease, Figure 3B, Figure 5B
and Figure S3A–D, S4A–D). The live DN population after zVAD/NaN3 or Etop treatment showed
a decrease or increase of DDR compared with drugs alone, respectively (Figure 3C, Figure 5C and
Figure S3D, S4D). Live RIP1-dependent apoptotic and resting phenotypes, after both treatments with
zVAD, showed increased DDR compared with drugs alone (Figure 3C, Figure 5C and Figure S3B,C,
S4B,C). Dead cells from zVAD blockade of NaN3/Etop treatments returned pH2AX and cleaved PARP
expression to that of untreated dead cells (Figure 3, Figure 5 and Figure S3E–H, S4E–H). Except after
NaN3/zVAD treatment, an increase in DDR was observed in the dead RIP1-dependent apoptotic and
oncotic DN phenotypes (Figure 5 and Figure S3F,H).
2.4. Blockade with Necrostatin-1
Blockade of NaN3 with Nec-1 resulted in very high levels of early apoptosis compared with NaN3,
but was lower with Etop treatment (Figure 1D,H). Cell death was lower with Nec-1/NaN3 but not
changed with Etop treatment (Figure 1D,H). The live cells showed a higher incidence of early and
RIP1-dependent apoptosis compared with NaN3 treatment, with no change observed with Etop or in
the incidence of dead cells (Figure 2A–D,G,H and Figure 4A,E,F).
pHA2X hyper-activation of cleaved PARP in live and dead cells after Nec-1 showed increased
values similar to that observed with only drugs, except for the lower levels in both the DN populations
and live resting cells after Nec-1/Etop treatment (Figure 3A, Figure 5A and Figure S3I–P, S4I–P).
Apoptosis via cleaved PARP was increased in live and dead cells after Nec-1 blockade of NaN3
treatment and decreased with Nec-1/Etop treatment compared with drugs alone, except for a decrease
in live resting cells (Nec-1/NaN3) and no change in RIP1-dependent apoptosis after Nec-1/Etop
treatment (Figure 3B, Figure 5B and Figure S3I–P, S4I–P). Very low levels of DDR were observed in
early and live RIP1-dependent apoptotic cells, but increased in live resting and DN cells (Figure 3C,
Figure 5C and Figure S3I–L, S4I–L). Dead cell phenotypes after Nec-1 blockade of NaN3 showed
no increase in DDR compared with untreated cells, but was increased with Nec-1/Etop treatment
(Figure 3C, Figure 5C and Figure S3, S4M–P).
2.5. Blockade with zVAD and Necrostatin-1
Pre-treatment with zVAD and Nec-1 to block the activation of caspases and RIP proteins resulted
in lower levels of early and late apoptosis (<20%), although oncosis (caspase-3–ve/Zombie+ve) was still
maintained (Figure 1E,I, Figure 2I,J and Figure 4G,H). Blocked NaN3 treated cells had a higher level of
live DN cells (and Etop), whereas dead cells showed higher levels of RIP1-dependent apoptosis, which
indicated that zVAD did not block caspases in the RIP1-dependent apoptotic pathway in the presence
of Nec-1 (Figure 2I,J and Figure 4G,H).
All cell phenotypes after dual blockade showed the same reduced levels of pH2AX hyper-activation
of cleaved PARP as that observed after zVAD blockade (no change in Etop DN cells, Figure 3A, Figure 5A
and Figure S3Q–X, S4Q–X). Apoptosis via cleaved PARP was lower in the early apoptotic and DN cells
after dual blockade of NaN3 and increased in live resting and RIP1-dependent apoptotic cells (Figure 3B
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and Figure S3Q,T). In contrast, all live cell (dual-blocked Etop) populations showed no change in
apoptosis via cleaved PARP compared with drug treatment, except for the lower levels observed in
live resting cells (Figure 5B and Figure S4Q,T). All dead cell populations after dual blockade of both
treatments showed lower levels of apoptosis via cleaved PARP compared to any treatment protocol,
except no change was observed in Etop-induced late and RIP1-dependent apoptotic cells (Figure 3B,
Figure 5B and Figure S3U–X, S4U–X). Lastly, the DDR levels after both treatment protocols showed
that all cell populations had higher levels than untreated cells (Figures 3C and 5C), except for the lower
levels found in the live RIP1-dependent apoptotic cells compared with both treatments (Figures 3C
and 5C).
3. Discussion
The use of oncosis and apoptosis-inducing drugs NaN3 and Etop, together with caspase and RIP
protein blockers, zVAD and Nec-1, has allowed the tracking of the cell death processes involved in
ACD and apoptosis a form of RCD using flow cytometry (Figure 6) [17–19]. Induction of oncosis or
apoptosis resulted in measurable oncosis (Zombie+ve/caspase-3–ve, commonly termed necrotic) but
also early and late apoptosis, which was reduced by zVAD blockade without affecting the degree of
oncosis induced by both drugs. Blockade of both drugs with Nec-1 resulted in increased NaN3-induced
early apoptosis while increasing Etop-induced oncosis. Induction of ACD and early apoptosis (by
NaN3) showed that live resting Jurkat cells move the RIP3+ve/caspase-3–ve/Zombie–ve phenotype to
the early apoptotic phenotype of RIP3–ve/caspase-3+ve/Zombie–ve, then later to the RIP1-dependent
phenotype RIP3+ve/caspase-3+ve/Zombie–ve (Figure 6B), even in the presence of RIP1 inhibitor, Nec-1.
This effect has been previously reported [17,19], where it was shown that although Nec-1 inhibited
necroptosis by abrogation of the up-regulation of RIP3 (RIP3+ve/caspase-3–ve/Zombie–ve), it did not
inhibit cells from undergoing apparent RIP1-dependent apoptosis. The limitation of the current assay
is highlighted by the use of RIP3 and caspase-3 antibodies to indirectly identify RIP1-dependent
apoptosis due to the lack availability of a fluorescenated RIP1 antibody [17,19]. The interactions of
RIP1, RIP3, TRADD (TNFR1-associated death domain), FADD (Fas associated via death domain),
and caspase-8 in apoptotic Complex IIa and IIb pathways are not completely understood, so another
explanation of the apparent presence (indirectly via RIP3) of RIP1-dependent apoptosis in the presence
of Nec-1 is required, which may be elucidated by the use of a fluorescenated RIP1 antibody [5,20,21].
Induction of apoptosis by Etop showed that a high proportion of live resting cells become DN
(losing their RIP3), as well as another population expressing caspase-3, possibly indicating that the
cells first lose RIP3, become DN, and then express caspase-3 (Figure 6B), but also that early apoptotic
cells can also later express RIP3 (Figure 6B) [5,17,19–21]. The route to RIP1-dependent apoptosis may
be that these resting cells, rather than lose their RIP3, also start to express caspase-3 (Figure 6B).
Once the cells lose plasma membrane integrity and become Zombie+ve, the cells presumably
maintain the late apoptotic phenotype RIP3–ve/caspase-3+ve/Zombie+ve before further degradation
resulting in the cells becoming DN (Figure 6C). Oncotic cells (caspase-3–ve/Zombie+ve) induced by
NaN3/Etop, however, can also be divided into those with RIP3+ve/caspase-3–ve/Zombie+ve or the DN
phenotype RIP3–ve/caspase-3–ve/Zombie+ve (Figure 6C).
Int. J. Mol. Sci. 2019, 20, 4379 10 of 13
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 9 of 13 
 
5B, S3U–X, S4U–X). Lastly, the DDR levels after both treatment protocols showed that all cell 
populations had higher levels than untreated cells (Figures 3C, 5C), except for the lower levels found 
in the live RIP1-dependent apoptotic cells compared with both treatments (Figures 3C, 5C). 
3. Discussion 
The use of oncosis and apoptosis-inducing drugs NaN3 and Etop, together with caspase and RIP 
protein blockers, zVAD and Nec-1, has allowed the tracking of the cell death processes involved in 
ACD and apoptosis a form of RCD using flow cytometry (Figure 6) [17–19]. Induction of oncosis or 
apoptosis resulted in measurable oncosis (Zombie+ve/caspase-3–ve, commonly termed necrotic) but 
also early and late apoptosis, which was reduced by zVAD blockade without affecting the degree of 
oncosis induced by both drugs. Blockade of both drugs with Nec-1 resulted in increased NaN3-
induced early apoptosis while increasing Etop-induced oncosis. Induction of ACD and early 
apoptosis (by NaN3) showed that live resting Jurkat cells move the RIP3+ve/caspase-3–ve/Zombie–ve 
phenotype to the early apoptotic phenotype of RIP3–ve/caspase-3+ve/Zombie–ve, then later to the RIP1-
dependent phenotype RIP3+ve/caspase-3+ve/Zombie–ve (Figure 6B), even in the presence of RIP1 
inhibitor, Nec-1. This effect has been previously reported [17,19], where it was shown that although 
Nec-1 inhibited necroptosis by abrogation of the up-regulation of RIP3 (RIP3+ve/caspase-3–ve/Zombie–
ve), it did not inhibit cells from undergoing apparent RIP1-dependent apoptosis. The limitation of the 
current assay is highlighted by the use of RIP3 and caspase-3 antibodies to indirectly identify RIP1-
dependent apoptosis due to the lack availability of a fluorescenated RIP1 antibody [17,19]. The 
interactions of RIP1, RIP3, TRADD (TNFR1-associated death domain), FADD (Fas associated via 
death domain), and caspase-8 in apoptotic Complex IIa and IIb pathways are not completely 
understood, so another explanation of the apparent presence (indirectly via RIP3) of RIP1-dependent 
apoptosis in the presence of Nec-1 is required, which may be elucidated by the use of a fluorescenated 
RIP1 antibody [5,20,21]. 
Induction of apoptosis by Etop showed that a high proportion of live resting cells become DN 
(losing their RIP3), as well as another population expressing caspase-3, possibly indicating that the 
cells first lose RIP3, become DN, and then express caspase-3 (Figure 6B), but also that early apoptotic 
cells can also later express RIP3 (Figure 6B) [5,17,19–21]. The route to RIP1-dependent apoptosis may 
be that these resting cells, rather than lose their RIP3, also start to express caspase-3 (Figure 6B). 
 
Figure 6. ACD and RCD pathways. (A) Live cells can undergo either early apoptosis (EAPO) or 
oncosis after drug treatment, with early apoptotic cells moving to late apoptotic (LAPO), then later 
Figure 6. ACD and RCD pathways. (A) Live cells can undergo either early apoptosis (EAPO) or oncosis
after drug treatment, with early apoptotic cells moving to late apoptotic (LAPO), then later with cell
degradation, to the oncotic or necrotic phenotype. (B) Live cells may express RIP3+ve/caspase-3–ve
when resting, or be RIP3high+ve/caspase-3–ve when undergoing necroptosis, or be double negative
(DN). EAPO cells lose RIP3 or, if retained, undergo RIP1-dependent apoptosis (RIP1-APO). EAPO
cells can also become RIP1+ve. (C) Loss of plasma membrane integrity or cell death results in cell
phenotypes mirrored in (B), with degradation of cells resulting in the DN population. (B,C) Live and
dead cell phenotypes can also express pH2AX (DDR) or cleaved PARP (apoptosis), both of which can
ultimately express both proteins, (D,E) resulting in pH2AX hyper-activation of cleaved PARP in the
presence of active caspase-3 or parthanatos in the absence of caspase-3. Arrows indicate movement of
cell populations.
The expression of pH2AX and cleaved PARP in the four identified phenotypes in live and dead
cells are resting, early or late apoptotic, RIP1-dependent apoptosis, and DN, the incidence of which is
modified by the action of the two drugs used in this study and can be further manipulated by blockade
of ACD and RCD processes by zVAD and Nec-1 (Figure 6D,E) [22–25]. In the first instance live resting
cells, the main phenotype of untreated Jurkat cells express RIP3 with a high degree of DDR (37%),
whereas resting DN cells showed little DDR (2%) but a high degree of cleaved PARP (39%) in the
absence of caspase-3 [25]. Induction of ACD resulted in enhanced levels of pHA2X hyper-activation of
cleaved PARP in all live cell phenotypes with consequent reduced levels of DDR in live RIP1-dependent
apoptotic cells, but with increased levels in the live DN phenotype (Figure 6D).
Once the cells undergo death, all phenotypes still showed increased pHA2X hyper-activation of
cleaved PARP above the levels observed with dead untreated Jurkat cells (Figure 6E), whereas late
apoptotic and dead oncotic DN cells showed increased DDR with no change in dead resting cells.
Similar results were observed when cells undergo Etop-induced apoptosis, except no increase in DDR
was observed in the dead oncotic or resting cells. So, NaN3-derived oncotic cells can express more
DDR than Etop-induced oncotic cells, which expressed higher levels of cleaved PARP (in the absence of
caspase-3) and parthanatos/pHA2X hyper-activation of cleaved PARP, again in the absence of caspase-3
(Figure 6E).
The main effect of blockade with zVAD was an increased incidence of live and dead DN cells
with both treatments, which displayed no change in DDR, increased cleaved PARP and reductions in
pHA2X hyper-activation of cleaved PARP, as was the case with most cell phenotypes (Figure 6D, E).
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This was with the notable exception of no change in levels of cleaved PARP in dead oncotic resting and
DN cells compared to NaN3 treatment.
In contrast, blockade of NaN3 with Nec-1 resulted in no change in the incidence of dead DN and
fewer live DN cells (as untreated cells), whereas Etop-induced levels were similar to that observed by
drug alone. However, all blocked NaN3 cell phenotypes showed increased cleaved PARP and pH2AX
activation of cleaved PARP with reductions in DDR; this observation was especially noteworthy in the
dead oncotic resting and DN cells, whereas the opposite was observed in these populations after Nec-1
blockade of Etop.
Dual blockade of both treatments again showed a high incidence of DN cells with reduced levels
of pHA2X hyper-activation of cleaved PARP and cleaved PARP expression in the various populations
of cells, whereas DDR was generally increased after Nec-1 blockade of both drugs in most populations
of cells. So, the blockade of apoptotic and/or necroptotic pathways when the cells are undergoing ACD
and RCD processes radically increased the incidence of oncotic cells, especially in the case of blockade
of apoptosis alone and necroptosis, which resulted in increased levels of DDR, whereas Nec-1 blockade
reduced ACD-related DDR but not in the case of RCD.
For decades, oncotic cells have been an undetermined population of dead cells that have been
overlooked due to the difficult in their characterisation rather than being a point of interest. They have
been detected by use of the Annexin V assay and classed as cell viability+ve/Annexin V–ve [13,15,16].
Using an active caspase-3 and RIP3 antibodies in tandem with a fixable live/dead dye, we showed that
these oncotic cells have two main phenotypes, both of which are cell viability+ve/caspase-3–ve/RIP3+/–ve,
which can be further divided into DDR, hyper-activation of PARP or parthanatos, apoptosis via PARP
or cells undergoing programmed necrosis, as well as double negative oncotic cells. All of them are
expressed to different degrees compared with cells derived from untreated cultures. This perhaps
reflects their different origins, with differences in expression of these markers when the cells are derived
from an ACD or RCD induction process. These differences in origin are further highlighted by their
differing oncotic responses to blockade by zVAD and Nec-1 or both.
4. Materials and Methods
4.1. Induction of Oncosis and Apoptosis
Jurkat cells (human acute T cell leukaemia cell line, ECACC, Salisbury, UK) were grown in RPMI
(Roswell Park Memorial Institute 1640 Medium) 1640 with 10% FBS (Fetal Bovine Serum, Invitrogen,
Paisley, UK) at 37 ◦C and 5% CO2, either untreated or treated with 0.25% sodium azide or 1 µM
etoposide (NaN3, Etop, Sigma, Poole, UK) for 24 h. Cells were pre-treated with pan-caspase blocker
zVAD (20 µM, Enzo Life Sciences, Exeter, UK) and/or necroptosis blocker necrostatin-1 (Nec-1, 60 µM
Cambridge Bioscience, Cambridge, UK) for 2 h before induction of oncosis with 0.25% sodium azide or
apoptosis with 1 µM Etop for 24 h.
4.2. Flow Cytometry Assay
Harvested cells were labelled with fixable live dead stain, Zombie near infra red (NIR; Biolegend,
San Diego, CA, USA) at room temperature (RT) for 15 min. Washed cell were fixed in Solution A
(CalTag, Little Balmer, UK) then 0.25% Triton X-100 (Sigma, Poole, UK) for 15 min each at RT. Jurkat
cells (1 × 106) were incubated for 20 min at RT with anti-RIP3-PE (phycoerythrin clone B-2, Cat. No.
sc-374639, Santa Cruz, Dallas, Tx, USA), cleaved PARP-PE-CF-595 (clone F21-852, Becton Dickinson,
San Jose, CA, USA), H2A.X-Phospho (ser139)-PE-Cy7 (clone 2F3, Biolegend, San Diego, CA, USA) and
anti- active caspase-3-BV650 (clone C92-605, Becton Dickinson, San Jose, CA, USA) for 20 min at RT.
Washed cells were resuspended in 400 µL PBS (Phosphate Buffered Saline) and analysed on a ACEA
Bioscience Novocyte 3000 flow cytometer (100,000 events, San Diego, CA, USA). Zombie NIR was
excited by a 633 nm laser and collected with a 780/60 nm detector. Caspase-3-BV650 was excited by a
405 nm laser and collected at 675/30 nm. RIP3-PE, cleaved PARP-PE-CF-595, and pH2AX-PE-Cy7 were
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excited by a 488 nm laser and collected at 572/28, 615/20, and 780/60 nm, respectively. Single colour
controls were used to determine the colour compensation using the pre-set voltages on the instrument
using Novo Express software (ver 1.2.5, ACEA Biosciences, San Diego, CA, USA). Cells were gated on
FSC (Forward Scatter) vs. SSC (Side Scatter) with single cells being gated on a FSC-A (Area) vs. FSC-H
(Height) plot. Cells were then gated on a plot of caspase-3-BV650 vs. Zombie NIR, with a quadrant
placed marking off live cells in the double negative quadrant (Figure S1A, lower left quadrant), with
caspase-3-BV650+ve/Zombie NIR–ve (Figure S1A, lower right quadrant) indicating early apoptotic
cells (EAPO), and lastly with caspase-3-BV650+ve/Zombie NIR+ve and caspase-3-BV650–ve/Zombie
NIR+ve (Figure S1A, upper quadrants) indicating dead late apoptotic (LAPO) (Figure S1A, upper right
quadrant) and oncotic cells (Figure S1A, upper left quadrant). Further labelling with RIP3 allowed
identification within the live resting and dead oncotic populations of RIP3+ve/caspase-3–ve or necroptotic
cells when RIP3 is up-regulated, early or late apoptotic (RIP3–ve/caspase-3+ve), RIP1-dependent
apoptosis (RIP3+ve/caspase-3+ve, RIP1APO), and live double negative (DN) or dead oncotic DN
cells (Figure S1B,D). Further gating on each of these eight populations for pH2AX and cleaved
PARP allowed the identification of DDR (H2AX+ve/PARP–ve), pH2AX hyper-activation of cleaved
PARP or parthanatos (H2AX+ve/PARP+ve), apoptotic cell death via cleaved PARP (H2AX–ve/PARP+ve),
and DN cells (H2AX–ve/PARP–ve) (Figure S1C,E) [19]. In particular, dead resting oncotic cells
(Zombie+ve/caspase-3–ve/RIP3+ve) and dead oncotic DN cells (Zombie+ve/caspase-3–ve/RIP3–ve) were
gated for pH2AX and cleaved PARP, revealing the phenotypic nature of these two types of oncotic
cells (Figure S1F,G).
4.3. Statistics
For all experiments, n = 3 and data are reported as mean ± SEM for percentage positive. Student’s
t-tests were performed in GraphPad software Inc. (San Diego, CA, USA) with p ≥ 0.05 considered not
significant (NS). * denotes p ≤ 0.05, ** denotes p ≤ 0.01, and *** denotes p ≤ 0.001 when treated cells
were compared to untreated cells.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/18/
4379/s1.
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